# Home blood pressure and falls among older adults

> **NIH NIH R01** · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2021 · $384,285

## Abstract

Cardiovascular disease (CVD) is the leading cause of death among older US adults. Over 75% of US adults ≥
65 years of age have hypertension, a major risk factor for CVD. Randomized controlled trials have
demonstrated that lowering blood pressure (BP) through antihypertensive medication reduces the risk for CVD
by 20% to 40% among older adults with hypertension. Many older US adults have uncontrolled BP and may
receive CVD risk reduction benefits from intensifying their antihypertensive medication. However, clinicians
are often concerned that intensively lowering BP may increase the risk for a fall. Falls are the leading cause of
injury-related hospitalization and death among older US adults and more than one in three US adults ≥ 65
years of age experience a fall each year. BP has traditionally been measured in the clinic setting and a major
challenge that clinicians encounter in deciding to titrate antihypertensive medication is the inaccuracy of BP
assessed in this setting. Home blood pressure monitoring (HBPM) is an inexpensive and highly feasible
approach to measure BP outside of the clinic setting and has the potential to improve BP control and,
therefore, reduce CVD risk. Whether HBPM can identify patients for whom antihypertensive medication can be
intensified without increasing the risk for a fall is unknown. A newly NIH-funded (July 1, 2018 to June 30, 2022)
prospective cohort study (AMBulatoRy blOod preSsure In older Adults [AMBROSIA]) will evaluate the
association of BP, measured outside of the clinic setting using ambulatory blood pressure monitoring (ABPM),
with falls risk among 1,057 adults aged ≥ 65 years, taking antihypertensive medication from the Kaiser
Permanente Southern California (KPSC) health system. ABPM was chosen for the AMBROSIA study as it is
considered the gold-standard approach for assessing out-of-clinic BP. Compared to ABPM, HBPM is more
widely available in the US and better tolerated by patients. The AMBROSIA study is not funded to perform
HBPM. The overall goal of the proposed ancillary study to AMBROSIA is to determine whether BP on HBPM
can identify older adults taking antihypertensive medication who are at increased risk for falls, and whether
HBPM provides similar predictive value for falls when compared with ABPM. AMBROSIA will begin study visits
in February 2019 and the proposed ancillary study (AMBROSIA-HOME) will add the conduct of HBPM for 7
days, with two BP measurements obtained in the morning and two BP measurements obtained in the evening
on each day, following the conduct of ABPM for 1,000 participants. Conducting the AMBROSIA-HOME study
will be cost-efficient as information on demographic and clinical characteristics, geriatric assessments,
research-grade BP measurements, and 24-hour ABPM is already being collected at baseline with falls and
serious fall injuries being assessed during a one-year follow-up period. The AMBROSIA-HOME study will
provide valuable data on the role of HBPM to personalize c...

## Key facts

- **NIH application ID:** 10163695
- **Project number:** 5R01HL147601-03
- **Recipient organization:** UNIVERSITY OF ALABAMA AT BIRMINGHAM
- **Principal Investigator:** Paul Muntner
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $384,285
- **Award type:** 5
- **Project period:** 2019-07-15 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10163695

## Citation

> US National Institutes of Health, RePORTER application 10163695, Home blood pressure and falls among older adults (5R01HL147601-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10163695. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
